CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.3150
+0.0060 (1.94%)
Apr 29, 2026, 2:33 PM EST
CytoDyn Earnings Call Transcripts
Fiscal Year 2025
-
Lorazumab is advancing in clinical trials for solid tumors, with strong safety and promising efficacy data, especially in triple-negative breast cancer. Market opportunities are significant, and regulatory progress includes Fast Track status for TNBC. Financial strategies and expanded access programs are underway.
Fiscal Year 2024
-
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals preliminarily approved. Final voting results will be reported in the meeting minutes and a Form 8-K filing.